Compare Stanley Black & Decker, Inc. (SWK) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs Tango Therapeutics Inc. — how do they compare? Stanley Black & Decker, Inc. trades at $90.33 (market cap $13.64B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Stanley Black & Decker, Inc. is far larger — about 3.6× Tango Therapeutics Inc.'s market cap, and Stanley Black & Decker, Inc. pays a 3.72% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stanley Black & Decker, Inc. for 62 Days and Tango Therapeutics Inc. for 0 Days on average.
| SWK | TNGX | |
|---|---|---|
Market Cap | $13.64B | $3.74B |
Volume | 1,097,590 | 3,438,781 |
Sector | Industrials | Health |
52-Week High | $104.00 | $32.90 |
52-Week Low | $62.12 | $7.50 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $17.80B | $2.76B |
Dividend Yield | 3.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stanley Black & Decker (SWK) trades at $90.71, up 2.32% today, with a bearish technical outlook but improving fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue remains stable around $15.1B, while net income margin improved to 2.65% in 2025. Valuation ratios show a P/E of 22.18 and P/S of 0.9, indicating reasonable pricing relative to sales. Recent news highlights product launches and dividend payments, with the company focusing on margin gains and brand strength.
SWK presents a mixed outlook: analyst consensus is cautious with a $93 price target, but fundamentals are strengthening with projected 2026 net income growth. Key risks include competitive pressures and macroeconomic headwinds, while opportunities lie in operational execution and market share gains. The stock's current level near consensus target suggests limited upside unless earnings surprises materialize.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
